^
BIOMARKER:

Chr del(17)(p13)

News
Twitter
Trials
Chr del(17)(p13)
Multiple Myeloma
bortezomib
Sensitive: A2 - Guideline
Chr del(17)(p13)
CLL
ibrutinib
Resistant: C3 – Early Trials
Chr del(17)(p13)
Multiple Myeloma
ixazomib
Sensitive: C3 – Early Trials